The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 8 February 2005, www.theannals.com, DOI 10.1345/aph.1E177.
 The Annals of Pharmacotherapy: Vol. 39, No. 3, pp. 481-491. DOI 10.1345/aph.1E177
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalus, J. S
Right arrow Articles by Moser, L. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalus, J. S
Right arrow Articles by Moser, L. R

CARDIOLOGY

Evolving Role of Low-Molecular-Weight Heparins in ST-Elevation Myocardial Infarction

James S Kalus, PharmD BCPS (Added Qualifications, Cardiology)

Assistant Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI; Clinical Pharmacy Specialist, Department of Pharmacy Services, Henry Ford Hospital, Detroit

Lynette R Moser, PharmD

Assistant Clinical Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University; Clinical Pharmacy Specialist, Department of Pharmacy Services, St. John Hospital, Detroit

Reprints: Dr. Moser, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Ste. 2190, Detroit, MI 48201-2427, fax 313/577-5369, lynette.moser{at}wayne.edu

OBJECTIVE: To review the available literature on the efficacy and safety of low-molecular-weight heparin (LMWH) in the treatment of ST-elevation myocardial infarction (STEMI) in patients treated with fibrinolytic therapy or conservative medical management.

DATA SOURCES: A MEDLINE search (1966-March 2004) using the key words myocardial infarction, STEMI, LMWH, enoxaparin, and dalteparin identified pertinent articles. The references of these articles were reviewed for additional pertinent references.

STUDY SELECTION AND DATA EXTRACTION: All human trials of LMWH in STEMI were evaluated. All pertinent studies were included in the review.

DATA SYNTHESIS: LMWH did not show a benefit in STEMI without fibrinolytic therapy. Enoxaparin is similar to intravenous unfractionated heparin (UFH) in combination with nonspecific fibrinolytic therapy with regard to invasive reperfusion markers and 30-day clinical outcomes. Enoxaparin decreases composite endpoints in combination with fibrin-specific fibrinolytic therapy compared with UFH, primarily through a reduction in the incidence of reinfarction at 30 days. Bleeding rates with LMWH in combination with fibrinolytic agents are not greater than those with UFH.

CONCLUSIONS: Enoxaparin is a reasonable alternative to UFH in patients with STEMI treated with fibrin-specific fibrinolytic therapy. LMWH in patients managed with nonspecific fibrinolytic therapy or conservative medical treatment does not provide an advantage over standard management. Large clinical trials are ongoing which will provide more definitive recommendations.

Key Words: dalteparin, enoxaparin, fibrinolytic agents, myocardial infarction

Published Online, February 8, 2005. www.theannals.com, DOI 10.1345/aph.1E177

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-009-H01




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.